Analyst Tom Mackinnon of BMO Capital maintained a Hold rating on IGM Financial (IGIFF – Research Report), retaining the price target of ...

IGM Biosciences (IGMS – Research Report) received a Sell rating and a $2.00 price target from Morgan Stanley analyst Michael Ulz today. The ...

Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval. Read why I maintain my Sell ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

IGM Financial Inc. (TSE:IGM – Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of C$41.15 and traded as high as C$46.21. IGM ...

IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.